Abstract: A method for treating obesity in a patient, the method comprising administering a dose of a GLP1 agonist to the patient in a treatment regimen effective to manage the patient's satiety and thereby effect a reduction in the patient's weight; and, in conjunction with the administration of the dose of GLP1 agonist, engaging in a directed digital therapeutic program that manages patient weight loss and the treatment regimen for the GLP1 agonist with the objective of achieving a predetermined target weight for the patient, wherein the patient achieves the target weight.

Abstract: The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

Abstract: The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

Abstract: The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

Abstract: The present disclosure relates to monitoring patient compliance with a dosage regimen. In some aspects, a patient unique identifier, which enables a patient to be uniquely identified and associated with a patient record, is received. A message is received. The message includes a package unique identifier that enables a package that a drug administered to the patient was stored within to be uniquely identified. The message includes at least one pair of values, wherein each pair of values corresponds to an administration event and indicates an amount of the drug administered to the patient and a time of administration of the amount of the drug to the patient. The drug administered to the patient using the package unique identifier is identified. The identity of the drug and the at least one pair of values are stored against the patient record, which includes a dosage regimen associated with the patient.

Abstract: The present invention pertains to compounds and polymers which incorporate a boronic acid sensor group (SG) of the formula (I): wherein: J is independently —CH2— or —CH2CH2—; n is independently 0, 1, 2, or 3; and each RR, if present, is independently a ring substituent; and wherein the ring attachment (i.e., where sensor group is attached) is via the 3-, 4-, 5-, or 6-ring position. Such compounds and polymers are useful in the selective chemical detection and/or quantitation of alpha-hydroxy carboxylic acids, such as lactic acid/lactate and malic acid/malate. The present invention also pertains to methods of preparing such compounds and polymers; methods and assays which employ these compounds and polymers; devices (e.g., holographic sensors) and kits for use in such methods and assays, etc.

Abstract: A sensor for the detection of an analyte comprising a cis-diol moiety, which comprises a holographic element comprising a medium and a hologram disposed throughout the volume of the medium, wherein an optical characteristic of the element changes as a result of a variation of a physical property occurring throughout the volume of the medium, and wherein the medium is a polymer comprising a group of formula (i) wherein n is 0, 1, 2, 3 or 4; each X (if present) is independently is an atom or group which, via an electronic effect, promotes formation of a tetrahedral geometry about the boron atom; and Y is a spacer which, when n is 0 or otherwise optionally, is an atom or group which, via an electronic effect, promotes formation of a tetrahedral geometry about the boron atom. Such a sensor may be used for the detection of glucose.

Abstract: A sensor for the detection of an analyte comprising a cis-diol moiety, which comprises a holographic element comprising a medium and a hologram disposed throughout the volume of the medium, wherein an optical characteristic of the element changes as a result of a variation of a physical property occurring throughout the volume of the medium, and wherein the medium is a polymer comprising a group of formula (I): wherein n is 0, 1, 2, 3 or 4; each X (if present) is independently is an atom or group which, via an electronic effect, promotes formation of a tetrahedral geometry about the boron atom; and Y is a spacer which, when n is 0 or otherwise optionally, is an atom or group which, via an electronic effect, promotes formation of a tetrahedral geometry about the boron atom. Such a sensor may be used for the detection of glucose.

Abstract: The present invention pertains to compounds and polymers which incorporate a boronic acid sensor group (SG) of the formula (I): wherein: J is independently —CH2— or —CH2CH2—; n is independently 0, 1, 2, or 3; and each RR, if present, is independently a ring substituent; and wherein the ring attachment (i.e., where sensor group is attached) is via the 3-, 4-, 5-, or 6-ring position. Such compounds and polymers are useful in the selective chemical detection and/or quantitation of alpha-hydroxy carboxylic acids, such as lactic acid/lactate and malic acid/malate. The present invention also pertains to methods of preparing such compounds and polymers; methods and assays which employ these compounds and polymers; devices (e.g., holographic sensors) and kits for use in such methods and assays, etc.